메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 25, Issue 10, 2007, Pages 1157-1159
Gynecologic oncology or medical oncology: What's in a name?
Author keywords

[No Author keywords available]
Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;
EID: 34247175381     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.2228     Document Type: Editorial
Times cited : (11)
References (9)
  • 1
    • 34247094747 scopus 로고    scopus 로고
    • Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
    • Silber JH, Rosenbaum PR, Polsky D, et al: Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy? J Clin Oncol 25:1169-1175, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 1169-1175
    • Silber, J.H.1    Rosenbaum, P.R.2    Polsky, D.3
  • 2
    • 19744368302 scopus 로고    scopus 로고
    • Cancer of the ovary
    • Cannistra SA: Cancer of the ovary. N Engl J Med 351:2519-2529, 2004
    • (2004) N Engl J Med , vol.351 , pp. 2519-2529
    • Cannistra, S.A.1
  • 3
    • 33646562149 scopus 로고    scopus 로고
    • Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study
    • Markman M, Blessing J, Rubin SC, et al: Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study. Gynecol Oncol 101:436-440, 2006
    • (2006) Gynecol Oncol , vol.101 , pp. 436-440
    • Markman, M.1    Blessing, J.2    Rubin, S.C.3
  • 4
    • 33750588670 scopus 로고    scopus 로고
    • Gemcitabine plus carboplatm compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An mtergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
    • Pfisterer J, Plante M, Vergote I, et al: Gemcitabine plus carboplatm compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An mtergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699-4707, 2006
    • (2006) J Clin Oncol , vol.24 , pp. 4699-4707
    • Pfisterer, J.1    Plante, M.2    Vergote, I.3
  • 5
    • 0035879099 scopus 로고    scopus 로고
    • Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    • Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001
    • (2001) J Clin Oncol , vol.19 , pp. 3312-3322
    • Gordon, A.N.1    Fleagle, J.T.2    Guthrie, D.3
  • 6
    • 23044495279 scopus 로고    scopus 로고
    • Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
    • Long HJ 3rd, Bundy BN, Grendys EC Jr, et al: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 23:4626-4633, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 4626-4633
    • Long 3rd, H.J.1    Bundy, B.N.2    Grendys Jr, E.C.3
  • 7
    • 23044471142 scopus 로고    scopus 로고
    • Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A Gynecologic Oncology Group Study
    • Monk BJ, Huang HQ, Cella D, et al: Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 23:4617-4625, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 4617-4625
    • Monk, B.J.1    Huang, H.Q.2    Cella, D.3
  • 8
    • 32944465867 scopus 로고    scopus 로고
    • Unique gene expression profile based on pathologic response in epithelial ovarian cancer
    • Spentzos D, Levine DA, Kolia S, et al: Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23:7911-7918, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 7911-7918
    • Spentzos, D.1    Levine, D.A.2    Kolia, S.3
  • 9
    • 12344267687 scopus 로고    scopus 로고
    • Gene expression signature with independent prognostic significance in epithelial ovarian cancer
    • Spentzos D, Levine DA, Ramoni MF, et al: Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22:4700-4710, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 4700-4710
    • Spentzos, D.1    Levine, D.A.2    Ramoni, M.F.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.